Renovaro Wins Expedited Trial to Enforce Merger Against Predictive Oncology

Renovaro Inc. has secured an expedited trial in 2025 for its lawsuit against Predictive Oncology, filed in the Delaware Court of Chancery, seeking to enforce a binding merger agreement executed on January 1, 2025. The merger agreement, which involved Predictive Oncology merging into Renovaro in exchange for a new class of preferred stock, prompted a more than 50% surge in Predictive Oncology's stock price after its public disclosure. Renovaro alleges that Predictive Oncology breached the agreement by conducting a $545,000 public securities offering in violation of exclusivity and good faith negotiation clauses, and by attempting to unilaterally terminate the merger agreement without meaningful negotiation. Renovaro is pursuing specific performance, injunctive relief, and damages to uphold shareholder value and enforce contractual obligations. The case, pending under Case No. 2025-0509, reflects Renovaro's commitment to enforcing merger terms and protecting corporate rights. Both companies are positioned in the biotech and diagnostics sectors, with Renovaro emphasizing its focus on AI-driven personalized medicine and cancer therapies.